775 results on '"Greco, F. Anthony"'
Search Results
2. International consensus on the initial diagnostic workup of cancer of unknown primary
3. Systematic review of the CUP trials characteristics and perspectives for next-generation studies
4. The role of site-specific therapy for cancers of unknown of primary: A meta-analysis
5. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset
6. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)
7. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium
8. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
9. Novel Diagnostic and Therapeutic Strategies in the Management of Patients with Cancers of Unknown Primary Site
10. Cancer of Unknown Primary Site
11. Data from A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
12. Supplementary Data from Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary
13. Supplementary Data from A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
14. Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma
15. Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
16. Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone
17. Germ Cell Neoplasms and Other Malignancies of the Mediastinum
18. Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay
19. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
20. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
21. A Retrospective Study of Treatment Outcomes in Patients With Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile
22. Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
23. A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
24. Non-Curative Chemotherapy for Patients with Unknown Primary Cancers
25. A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer
26. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care
27. Phase II Trial of Vinflunine in Relapsed Small Cell Lung Cancer
28. A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer
29. Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
30. Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
31. Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
32. The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.
33. Global Consensus on the Initial Diagnostic Workup of Cancer of Unknown Primary
34. Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
35. Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
36. A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer
37. Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer
38. Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
39. Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
40. A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib
41. Neuroendocrine Carcinoma of Unknown Primary Site
42. Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors
43. Overview of Patient Management and Future Directions in Unknown Primary Carcinoma
44. Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient Management
45. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
46. A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer
47. A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer
48. A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer
49. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
50. Molecular Classification of Cancers of Unknown Primary Site
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.